Medivir Financial Statement 1 Jan-31 Dec 2003

MEDIVIR FINANCIAL STATEMENT 1 January - 31 December 2003 · MIV-310 was outlicensed to Boehringer Ingelheim in July in a global licensing agreement with a total contract value of € 122 m. · MIV-210 was outlicensed in May to GlaxoSmithKline as part of a global licensing agreement with a total contract value of € 86 m of which Medivir received € 6 m at the time of signing the agreement. · In November, Roche and Medivir entered into two agreements within the field of virology. Within the HIV field, the companies restructured the existing collaborative agreement for MV026048 and, for hepatitis C, they entered into a new research partnership agreement. · In November, Medivir and Hengrui signed a research partnership agreement to develop drugs to combat chronic obstructive pulmonary disease (COPD). · In July, Medivir entered into a licensing agreement for MIV-150 with the Population Council. · In November, Medivir and Peptimmune Inc. were granted an EU patent for the use of Cathepsin S-inhibitor in therapeutic formulations for alleviating immune reactions. · Major progress has been made in the Cathepsin projects. · On 1 July, Medivir divested its subsidiary CCS for SEK 210 m. · Lars Adlersson entered the position as CEO and President on 1 March. · Net sales amounted to SEK 149.0 m inclusive CCS half-year (256.3 m inclusive CCS whole-year). Profit after tax were SEK -40.3 m (SEK -59.8 m), earnings per share amounted to SEK -4.69 (SEK -7.09). FOR FURTHER INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP IR, +46 (0)8 5468 3123 or +46 (0)708 537292 ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: The full report The full report

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR).